Coagulation in sepsis

[1]  F. R. Machado,et al.  Coagulation and sepsis. , 2006, Endocrine, metabolic & immune disorders drug targets.

[2]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[3]  S. Bateman,et al.  An updated view of hemostasis: mechanisms of hemostatic dysfuntion associated with sepsis , 2005 .

[4]  U. Nicolai,et al.  Hemostatic abnormalities and the severity of illness in patients at the onset of clinically defined sepsis , 1996, Intensive Care Medicine.

[5]  B. Jude,et al.  Protein C and S deficiency in severe infectious purpura of children: A collaborative study of 40 cases , 2005, Intensive Care Medicine.

[6]  V. Pettilä,et al.  Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation 1 , 2004, Journal of thrombosis and haemostasis : JTH.

[7]  N. Mackman,et al.  Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis. , 2004, Critical care medicine.

[8]  L. Freeman,et al.  Hemostatic changes in dogs with naturally occurring sepsis. , 2003, Journal of veterinary internal medicine.

[9]  C. Sprung,et al.  Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. , 2003, JAMA.

[10]  T. Iba,et al.  [Disseminated intravascular coagulation]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.

[11]  S. Idell.  Endothelium and disordered fibrin turnover in the injured lung: Newly recognized pathways , 2002, Critical care medicine.

[12]  K. Garces.  Activated protein C for severe sepsis. , 2002, Issues in emerging health technologies.

[13]  V. Brancaccio,et al.  Coagulation disorders in liver disease. , 2002, Seminars in liver disease.

[14]  S. Opal,et al.  Success or Failure in Phase III Sepsis Trials : Comparisons between the Drotrecogin Alfa ( Activated ) and Antithrombin III Clinical Trials , 2002 .

[15]  W. Schobersberger,et al.  Effects of Antithrombin III on Tumor Necrosis Factor-α and Interleukin-1β Synthesis in Vascular Smooth Muscle Cells , 2001 .

[16]  S. Zakynthinos,et al.  Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock , 2001, Intensive Care Medicine.

[17]  S. Opal,et al.  High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial , 2001 .

[18]  E. Gabazza,et al.  Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. , 2001, Thrombosis research.

[19]  Wei Huang,et al.  Role of thrombin signalling in platelets in haemostasis and thrombosis , 2001, Nature.

[20]  C. Kessler,et al.  D-dimer testing: the role of the clinical laboratory in the diagnosis of pulmonary embolism. , 2001, Journal of clinical pathology.

[21]  J. Morrissey,et al.  Tissue Factor: An Enzyme Cofactor and a True Receptor , 2001, Thrombosis and Haemostasis.

[22]  P. Reitsma,et al.  Microvascular coagulopathy and disseminated intravascular coagulation , 2001, Critical care medicine.

[23]  C. Esmon.  Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation , 2001, Critical care medicine.

[24]  T. van der Poll,et al.  Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. , 2001, The Journal of infectious diseases.

[25]  C. Esmon.  Role of Coagulation Inhibitors in Inflammation , 2001, Thrombosis and Haemostasis.

[26]  D. Monroe,et al.  A Cell-based Model of Hemostasis , 2001, Thrombosis and Haemostasis.

[27]  L. Gelbert,et al.  Gene Expression Profile of Antithrombotic Protein C Defines New Mechanisms Modulating Inflammation and Apoptosis* , 2001, The Journal of Biological Chemistry.

[28]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[29]  S. Opal,et al.  The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis , 2001, Critical care medicine.

[30]  W. Schobersberger,et al.  Effects of antithrombin III on tumor necrosis factor-alpha and interleukin-1beta synthesis in vascular smooth muscle cells. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[31]  J. Meijers,et al.  Regulation of Fibrinolysis in Plasma by TAFI and Protein C Is Dependent on the Concentration of Thrombomodulin , 2001, Thrombosis and Haemostasis.

[32]  S. Opal,et al.  Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. , 2001, JAMA.

[33]  S. Opal,et al.  Therapeutic rationale for antithrombin III in sepsis , 2000, Critical care medicine.

[34]  H. Okabe,et al.  Activated Protein C Reduces the Ischemia/Reperfusion-Induced Spinal Cord Injury in Rats by Inhibiting Neutrophil Activation , 2000, Annals of surgery.

[35]  R. Ransohoff,et al.  Endothelial cell expression of monocyte chemotactic protein-1, tissue factor, and thrombomodulin on hydrophilic plasma polymers. , 2000, Journal of biomedical materials research.

[36]  C. Esmon,et al.  The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. , 2000, Blood.

[37]  C. Esmon.  Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? , 2000, Blood.

[38]  T. van der Poll,et al.  Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. , 2000, Blood.

[39]  J. White,et al.  Thrombin facilitates primary platelet adhesion onto vascular surfaces in the absence of plasma adhesive proteins: studies under flow conditions. , 2000, Haematologica.

[40]  J. Fredenburgh,et al.  Mechanism of Action of Plasminogen Activators , 1999, Thrombosis and Haemostasis.

[41]  J. Peña,et al.  Time course and prognostic significance of hemostatic changes in sepsis: relation to tumor necrosis factor-alpha. , 1999, Critical care medicine.

[42]  S. Kushimoto,et al.  Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. , 1999, Blood.

[43]  B. Furie,et al.  The Biology of P-Selectin Glycoprotein Ligand-1: Its Role as a Selectin Counterreceptor in Leukocyte-Endothelial and Leukocyte-Platelet Interaction , 1999, Thrombosis and Haemostasis.

[44]  O. Kemmotsu,et al.  Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. , 1998, Critical care medicine.

[45]  G S Kansas,et al.  Important contributions of P-selectin glycoprotein ligand-1-mediated secondary capture to human monocyte adhesion to P-selectin, E-selectin, and TNF-alpha-activated endothelium under flow in vitro. , 1998, Journal of immunology.

[46]  B. Østerud.  Tissue factor expression by monocytes: regulation and pathophysiological roles. , 1998 .

[47]  B. Osterud.  Tissue factor expression by monocytes: regulation and pathophysiological roles. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[48]  J. Paramo,et al.  Acute generalized, widespread bleeding. Diagnosis and management. , 1998, Haematologica.

[49]  M. Uchiba,et al.  Antithrombin III (AT III) Prevents LPS-Induced Pulmonary Vascular Injury: Novel Biological Activity of AT III , 1997, Seminars in thrombosis and hemostasis.

[50]  P. Kubes,et al.  Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. , 1997, Circulation.

[51]  C. Kessler,et al.  The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. , 1997, Blood.

[52]  Kenneth G. Mann,et al.  Inhibitory Mechanism of the Protein C Pathway on Tissue Factor-induced Thrombin Generation , 1997, The Journal of Biological Chemistry.

[53]  Kenneth G. Mann,et al.  Regulation of Tissue Factor Initiated Thrombin Generation by the Stoichiometric Inhibitors Tissue Factor Pathway Inhibitor, Antithrombin-III, and Heparin Cofactor-II* , 1997, The Journal of Biological Chemistry.

[54]  K. Takatsuki,et al.  Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. , 1997, The American journal of physiology.

[55]  C. Esmon,et al.  The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Nesheim,et al.  The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. , 1996, Blood.

[57]  P. Mannucci,et al.  Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. , 1996, Blood.

[58]  D. Monroe,et al.  Transmission of a procoagulant signal from tissue factor‐bearing cells to platelets , 1996, Blood Coagulation and Fibrinolysis.

[59]  S. Gando,et al.  Cytokines, soluble thrombomodulin and disseminated intravascular coagulation in patients with systemic inflammatory response syndrome. , 1995, Thrombosis research.

[60]  D. Eaton,et al.  Plasma carboxypeptidases as regulators of the plasminogen system. , 1995, The Journal of clinical investigation.

[61]  C. McClain,et al.  Tumor necrosis factor reduces proteoglycan synthesis in cultured endothelial cells , 1995, Journal of cellular physiology.

[62]  J. T. ten Cate,et al.  Coagulation Activation and Tissue Necrosis in Meningococcal Septic Shock: Severely Reduced Protein C Levels Predict a High Mortality , 1995, Thrombosis and Haemostasis.

[63]  S. Grey,et al.  Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. , 1994, Journal of immunology.

[64]  M. McGee,et al.  Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation , 1994, The Journal of experimental medicine.

[65]  W. Hancock,et al.  P-selectin and platelet-activating factor mediate initial endotoxin- induced neutropenia , 1994, The Journal of experimental medicine.

[66]  M. Hoffman,et al.  Platelets contain releasable coagulation factor IX antigen , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[67]  P. Neuenschwander,et al.  Factor VII autoactivation proceeds via interaction of distinct protease-cofactor and zymogen-cofactor complexes. Implications of a two-dimensional enzyme kinetic mechanism. , 1993, The Journal of biological chemistry.

[68]  A. Chang,et al.  Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. , 1993, The Journal of clinical investigation.

[69]  J. Lorente,et al.  clinical investigations in critical care Time Course of Hemostatic Abnormalities in Sepsis and its Relation to Outcome * , 2006 .

[70]  P. Comp,et al.  Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. , 1993, Blood.

[71]  R. Heyderman,et al.  Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. , 1992, Journal of cell science.

[72]  Mosesson Mw.  The roles of fibrinogen and fibrin in hemostasis and thrombosis. , 1992 .

[73]  G. Broze.  Why do hemophiliacs bleed? , 1992, Hospital practice.

[74]  C. Chopin,et al.  Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. , 1992, Chest.

[75]  B. Hazenberg,et al.  Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute‐phase proteins during the treatment of severe sepsis in humans , 1992, Critical care medicine.

[76]  M. Mosesson.  The roles of fibrinogen and fibrin in hemostasis and thrombosis. , 1992, Seminars in hematology.

[77]  M. Blajchman,et al.  Molecular basis of inherited human antithrombin deficiency. , 1992, Blood.

[78]  W. Kisiel,et al.  Initiation of the extrinsic pathway of blood coagulation: evidence for the tissue factor dependent autoactivation of human coagulation factor VII. , 1991, Biochemistry.

[79]  C. Esmon,et al.  C4b-binding protein exacerbates the host response to Escherichia coli. , 1991, Blood.

[80]  H. Ishii,et al.  Soluble Thrombomodulin Antigen in Conditioned Medium Is Increased by Damage of Endothelial Cells , 1991, Thrombosis and Haemostasis.

[81]  J. Philippé,et al.  Fibrinolysis and Coagulation in Patients with Infectious Disease and Sepsis , 1991, Thrombosis and Haemostasis.

[82]  M. Blombäck,et al.  Protein C, Protein S and c4b-Binding Protein in Severe lnfection and Septic Shock , 1991, Thrombosis and Haemostasis.

[83]  H. Nawata,et al.  Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. , 1989, Biochemical and biophysical research communications.

[84]  M. Blombäck,et al.  Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. , 1989, Critical care medicine.

[85]  C. Esmon,et al.  The roles of protein C and thrombomodulin in the regulation of blood coagulation. , 1984, The Journal of biological chemistry.

[86]  R. Rosenberg,et al.  Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells , 1988, Molecular and cellular biology.

[87]  R. Jordan,et al.  Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. , 1988, Circulatory shock.

[88]  S. Bajaj,et al.  Expression of tissue factor and factor VIIa/tissue factor inhibitor activity in endotoxin or phorbol ester stimulated U937 monocyte-like cells. , 1988, Blood.

[89]  C. Esmon,et al.  Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. , 1987, The Journal of clinical investigation.

[90]  J. Griffin,et al.  Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. , 1986, Blood.

[91]  Y. Nemerson,et al.  Tissue factor accelerates the activation of coagulation factor VII: the role of a bifunctional coagulation cofactor. , 1985, Thrombosis research.

[92]  S. Rapaport,et al.  Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. , 1985, Blood.

[93]  R. Schaub,et al.  Early events in the formation of a venous thrombus following local trauma and stasis. , 1984, Laboratory investigation; a journal of technical methods and pathology.

[94]  W. Kisiel.  Human Plasma Protein C: ISOLATION, CHARACTERIZATION, AND MECHANISM OF ACTIVATION BY α-THROMBIN , 1979 .

[95]  W. Kisiel.  Human plasma protein C: isolation, characterization, and mechanism of activation by alpha-thrombin. , 1979, The Journal of clinical investigation.

[96]  B. Osterud,et al.  Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[97]  S. Pizzo,et al.  The effect of plasmin on the subunit structure of human fibrin. , 1973, The Journal of biological chemistry.

[98]  E. Marciniak.  Factor‐Xa Inactivation by Antithrombin III , 1973 .

[99]  S. Pizzo,et al.  The subunit structures of human plasma and platelet factor XIII (fibrin-stabilizing factor). , 1971, The Journal of biological chemistry.

[100]  E. Davie,et al.  Waterfall Sequence for Intrinsic Blood Clotting , 1964, Science.

[101]  Macfarlane Rg,et al.  AN ENZYME CASCADE IN THE BLOOD CLOTTING MECHANISM, AND ITS FUNCTION AS A BIOCHEMICAL AMPLIFIER , 1964 .

[102]  R. Macfarlane.  An Enzyme Cascade in the Blood Clotting Mechanism, and its Function as a Biochemical Amplifier , 1964, Nature.